AbbVie (NYSE:ABBV) Stock Price Down 2% – Should You Sell?

AbbVie Inc. (NYSE:ABBV)’s stock price dropped 2% on Thursday . The company traded as low as $223.02 and last traded at $224.1250. Approximately 5,294,746 shares changed hands during trading, a decline of 29% from the average daily volume of 7,508,581 shares. The stock had previously closed at $228.72.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA approved the VENCLEXTA® (venetoclax) + acalabrutinib combination for previously untreated chronic lymphocytic leukemia (CLL). This is the first all‑oral, fixed‑duration combo for this setting, supported by Phase 3 AMPLIFY data—it can meaningfully expand uptake for Venclexta and acalabrutinib, strengthen AbbVie’s oncology franchise and offer a durable revenue stream versus one‑off treatments. U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
• Positive Sentiment: Industry write‑ups frame the FDA approval as a potential new standard for a slow‑growing blood cancer, highlighting better three‑year outcomes and the “time off therapy” selling point—this can accelerate physician adoption and market share vs. chemo regimens. FDA Approval For AbbVie/AstraZeneca’s Combination Treatment Could Set New Standard For Slow Growing Blood Cancer
• Positive Sentiment: AbbVie opened a Phase 2a study for ABBV‑142 in idiopathic pulmonary fibrosis (IPF), broadening its respiratory/pulmonary pipeline beyond core immunology and oncology programs. Early‑stage pipeline depth helps investor sentiment around post‑Humira growth optionality. AbbVie Expands IPF Pipeline With New Phase 2a Study of ABBV-142
• Positive Sentiment: Board declared a $1.73 quarterly dividend (yield ~3.1%), reinforcing the income profile for dividend‑focused investors and supporting the stock’s defensive appeal. Dividend cadence and yield matter for total return expectations. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: Quarterly results and commentary show Rinvoq and Skyrizi continuing to drive top‑line growth and offset Humira erosion; that underpins management’s guidance but much of these dynamics are already reflected in recent estimates. Will Immunology Drugs Continue to Drive AbbVie’s Top Line in 2026?
• Neutral Sentiment: Coverage pieces ask whether AbbVie’s post‑Humira pipeline merits renewed investor attention — useful for narrative, but these are discussion pieces rather than new data that would immediately re‑rate the stock. Should AbbVie’s (ABBV) Post-Humira Pipeline Progress Prompt a Fresh Look From Investors?
• Neutral Sentiment: Marketing/PR items (new podcast, inclusion in dividend lists, media mentions) help brand and investor awareness but are unlikely to move fundamentals in the near term. AbbVie heads to ‘The Persistence Lab’ in new podcast highlighting healthcare innovation
• Negative Sentiment: Evercore noted Tremfya’s share gains but flagged possible limits to future earnings growth and trimmed its price target slightly—this is a modest analyst headwind that could cap upside if more firms follow with tepid updates. Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited

Wall Street Analyst Weigh In

ABBV has been the subject of a number of research reports. Berenberg Bank set a $275.00 target price on shares of AbbVie in a research note on Tuesday, January 20th. Scotiabank started coverage on AbbVie in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price target on the stock. JPMorgan Chase & Co. increased their price objective on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their target price for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Finally, Raymond James Financial set a $256.00 price target on shares of AbbVie in a research note on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $252.79.

AbbVie Stock Performance

The stock has a market cap of $397.56 billion, a PE ratio of 95.31, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35. The company’s 50-day moving average price is $224.04 and its 200 day moving average price is $221.89.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The company had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same period in the prior year, the business posted $2.16 earnings per share. The firm’s revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Diversified Trust Co increased its position in AbbVie by 23.6% in the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after acquiring an additional 10,891 shares during the period. Permanent Capital Management LP acquired a new position in shares of AbbVie in the third quarter valued at approximately $720,000. Railway Pension Investments Ltd raised its stake in shares of AbbVie by 33.0% during the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after purchasing an additional 211,800 shares during the last quarter. World Investment Advisors lifted its holdings in shares of AbbVie by 9.4% during the third quarter. World Investment Advisors now owns 113,925 shares of the company’s stock worth $26,378,000 after purchasing an additional 9,811 shares during the period. Finally, Charles Schwab Trust Co lifted its holdings in shares of AbbVie by 93.4% during the third quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock worth $7,434,000 after purchasing an additional 15,502 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.